CTKB250117C2500
- 3.71
- 0.000.00%
Cytek Biosciences Newsroom
Is Cytek Biosciences (NASDAQ:CTKB) A Risky Investment?
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Crude Oil Gains 1%; Chicago PMI Falls In December
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
Cytek Biosciences Announces $50M Stock Repurchase Program for 2025
Express News | Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
2024's 'Biggest Loses' That Could See Reversal in 2025
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Cuts Target Price to $8.25
In the Wake of Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Latest US$84m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions
Cytek Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $9
Cautious Hold on Cytek Biosciences Amid Recovery and Growth Opportunities
Cytek Biosciences Is Maintained at Overweight by Piper Sandler
Cytek Biosciences Analyst Ratings
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Raises Target Price to $8.5
Cytek Introduces Enhanced Small Particle Detection Option For Cytek Aurora CS System
Cytek Biosciences | 10-Q: Q3 2024 Earnings Report
Nasdaq Surges Over 500 Points; Johnson Controls Earnings Top Views
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results